Integra LifeSciences (NASDAQ:IART) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Integra LifeSciences (NASDAQ:IART) announced its quarterly earnings data on Tuesday. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13, FiscalAI reports. The company had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 EPS. Integra LifeSciences updated its FY 2026 guidance to 2.400-2.500 EPS and its Q2 2026 guidance to 0.440-0.520 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Leadership change: Stuart Essig has resumed the CEO role (retaining Chairman) with a long-term commitment and the company added Michael McBreen as Chief Commercial Officer to sharpen commercial execution, culture, and customer focus.
• Q1 beat and updated EPS guide: Q1 revenue was $392M and adjusted EPS $0.54 (above guidance); company maintained 2026 revenue guidance of $1.66B–$1.70B and raised full-year adjusted EPS to $2.40–$2.50, citing tariff benefits and operational improvements.
• Tissue Reconstruction momentum and reimbursement positioning: Tissue Reconstruction grew ~6.4% organic (strong Integra Skin, DermaClose, PriMatrix), and management says ~90% of wound reconstruction revenue is inpatient (not impacted by new CMS outpatient skin substitute rules) with the portfolio priced to compete under the new reimbursement framework.
• Quality, supply and product returns: The Compliance Master Plan remediation is progressing with improving supply reliability and Braintree production expected by end of June, but management says the 2026 guide does not rely on meaningful contribution from products still off-market.
• Cash flow and leverage path: Q1 operating cash flow improved to $9.8M, the company expects ~+$150M in operating cash flow vs. 2025, reports net debt of $1.6B and a 4.1x leverage ratio with a plan to approach target leverage of 2.5x–3.5x by end of 2026.

Integra LifeSciences Stock Performance

IART stock opened at $13.17 on Tuesday. The firm has a 50 day moving average of $10.09 and a two-hundred day moving average of $11.73. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $16.49. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.84 and a beta of 1.08. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently bought and sold shares of the business. Global Retirement Partners LLC bought a new position in Integra LifeSciences during the fourth quarter valued at about $25,000. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after acquiring an additional 6,814 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Integra LifeSciences in the 4th quarter valued at approximately $124,000. Finally, Amundi raised its stake in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after acquiring an additional 11,004 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.54 vs. $0.41 est; revenue $391.9M vs. $381.8M est, showing modest year-over-year growth and operating momentum. Integra LifeSciences Reports First Quarter 2026 Financial Results
• Positive Sentiment: Full-year FY2026 EPS guidance raised to $2.40–2.50, above consensus (~$2.35), signaling management confidence in longer?term profitability despite near-term headwinds. FY2026 Guidance in Press Release
• Neutral Sentiment: Leadership transition announced — Stuart Essig named President & CEO and Michael McBreen appointed Chief Commercial Officer; this provides clarity on succession but will take time to assess strategic impact. Leadership Transition Announcement
• Negative Sentiment: Near-term guidance came in light — Q2 EPS guide $0.440–0.520 (consensus ~$0.53) and revenue guide $410M–$425M (consensus ~$425.3M), which could pressure near-term estimates and cap upside until mid?year results. Q2 Guidance in Press Release

Analyst Ratings Changes

Several research firms have weighed in on IART. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Wells Fargo & Company upgraded shares of Integra LifeSciences to a “hold” rating in a report on Wednesday, March 18th. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Wall Street Zen downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Citigroup decreased their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research note on Wednesday, March 11th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $14.20.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.